Literature DB >> 9549723

Analysis of the PTEN gene in human meningiomas.

N Peters1, R Wellenreuther, B Rollbrocker, Y Hayashi, B Meyer-Puttlitz, E M Duerr, D Lenartz, D J Marsh, J Schramm, O D Wiestler, R Parsons, C Eng, A von Deimling.   

Abstract

Previous observations demonstrated that the neurofibromatosis type 2 gene (NF2) plays an important role in the pathogenesis of the transitional, fibroblastic and malignant variants of human meningiomas. No specific genes have been associated with the pathogenesis of meningothelial meningiomas and with the progression to anaplastic meningiomas. However, allelic losses on chromosomal arms 1p, 10q and 14q have been implicated in the process of malignant progression. Recently, PTEN (phosphatase and tensin homolog deleted on chromosome ten) also termed MMAC1 (mutated in multiple advanced cancers 1) or TEP1 (TGF--regulated and epithelial cell-enriched phosphatase), emerged as a candidate gene on chromosome 10q23.3. Initial studies revealed mutations of PTEN in limited series of glioblastomas, breast, kidney and prostate carcinomas mainly as cell lines. In order to evaluate the involvement of PTEN in the development of meningiomas, we have analysed the entire coding sequence of the gene in a series of 55 meningiomas (WHO grade I). 10 atypical meningiomas (WHO grade II) and 10 anaplastic meningiomas (WHO grade III). No PTEN mutations were seen in the WHO grade I meningiomas. However, one of the anaplastic meningiomas carried a somatic mutation. In addition, all tumours were examined for the presence of homozygous deletions of PTEN but these were not detected in any of the meningiomas. Our data suggest that mutations in PTEN are not involved in the formation of low grade meningiomas, but may contribute to malignant progression in a fraction of anaplastic meningiomas.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9549723     DOI: 10.1046/j.1365-2990.1998.00093.x

Source DB:  PubMed          Journal:  Neuropathol Appl Neurobiol        ISSN: 0305-1846            Impact factor:   8.090


  9 in total

1.  The p53/p21 DNA damage-signaling pathway is defective in most meningioma cells.

Authors:  Huda H Al-Khalaf; Boleslaw Lach; Ayman Allam; Ahmed AlKhani; Salman A Alrokayan; Abdelilah Aboussekhra
Journal:  J Neurooncol       Date:  2007-01-24       Impact factor: 4.130

Review 2.  Molecular pathogenesis of meningiomas.

Authors:  Arie Perry; David H Gutmann; Guido Reifenberger
Journal:  J Neurooncol       Date:  2004-11       Impact factor: 4.130

3.  Mutation and deletion analysis of GFR alpha-1, encoding the co-receptor for the GDNF/RET complex, in human brain tumours.

Authors:  O Gimm; A Gössling; D J Marsh; P L Dahia; L M Mulligan; A von Deimling; C Eng
Journal:  Br J Cancer       Date:  1999-05       Impact factor: 7.640

4.  Therapeutic radiation for childhood cancer drives structural aberrations of NF2 in meningiomas.

Authors:  Sameer Agnihotri; Suganth Suppiah; Peter D Tonge; Shahrzad Jalali; Arnavaz Danesh; Jeffery P Bruce; Yasin Mamatjan; George Klironomos; Lior Gonen; Karolyn Au; Sheila Mansouri; Sharin Karimi; Felix Sahm; Andreas von Deimling; Michael D Taylor; Normand J Laperriere; Trevor J Pugh; Kenneth D Aldape; Gelareh Zadeh
Journal:  Nat Commun       Date:  2017-08-04       Impact factor: 14.919

Review 5.  Familial Syndromes Involving Meningiomas Provide Mechanistic Insight Into Sporadic Disease.

Authors:  Keith Kerr; Krista Qualmann; Yoshua Esquenazi; John Hagan; Dong H Kim
Journal:  Neurosurgery       Date:  2018-12-01       Impact factor: 4.654

6.  EGFR, PIK3CA, KRAS and BRAF mutations in meningiomas.

Authors:  Mateusz Bujko; Paulina Kober; Andrzej Tysarowski; Ewa Matyja; Tomasz Mandat; Wiesław Bonicki; Janusz Aleksander Siedlecki
Journal:  Oncol Lett       Date:  2014-04-07       Impact factor: 2.967

7.  Molecular Targets and Treatment of Meningioma.

Authors:  Rickey Miller; Michele L DeCandio; Yaenette Dixon-Mah; Pierre Giglio; W Alex Vandergrift; Naren L Banik; Sunil J Patel; Abhay K Varma; Arabinda Das
Journal:  J Neurol Neurosurg       Date:  2014

8.  Multiple Meningiomas in a Patient with Cowden Syndrome.

Authors:  Margaret Pain; Armine Darbinyan; Mary Fowkes; Raj Shrivastava
Journal:  J Neurol Surg Rep       Date:  2016-07

9.  Distinct genomic subclasses of high-grade/progressive meningiomas: NF2-associated, NF2-exclusive, and NF2-agnostic.

Authors:  Erik A Williams; Sandro Santagata; Hiroaki Wakimoto; Ganesh M Shankar; Fred G Barker; Radwa Sharaf; Abhinav Reddy; Phoebe Spear; Brian M Alexander; Jeffrey S Ross; Priscilla K Brastianos; Daniel P Cahill; Shakti H Ramkissoon; Tareq A Juratli
Journal:  Acta Neuropathol Commun       Date:  2020-10-21       Impact factor: 7.801

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.